Abstract
Despite its potent in vitro anti-cancer activity, the vitamin E extract tocotrienol has its therapeutic potential hampered by its poor bioavailability and by its inability to reach tumors in a specific way after intravenous administration. One possibility to overcome this issue would be to entrap tocotrienol within vesicles bearing transferrin, whose receptors are present in abundance on many cancer cell types. In this study, we demonstrated that the systemic administration of tocotrienol entrapped within transferrin-bearing vesicles led to tumor suppression of 20% of A431 epidermoid carcinoma tumors and 50% of B16-F10 melanoma tumors at the end of the treatment. The survival of animals treated with these vesicles was improved by more than 20 days in comparison with the controls, for the two cancer models tested. Animals did not show any secondary effects following administration of the treatment. The entrapment of tocotrienol within transferrin-bearing vesicles is therefore a promising therapeutic strategy, which could result in tumor suppression after systemic administration of this delivery system.
Keywords: Cancer therapy, delivery system, in vivo, tocotrienol, transferrin, tumor targeting.
Pharmaceutical Nanotechnology
Title:Anti-Cancer Efficacy of Intravenously Administered Tumor- Targeted Vesicles Entrapping Tocotrienol
Volume: 2 Issue: 4
Author(s): Ju Yen Fu and Christine Dufes
Affiliation:
Keywords: Cancer therapy, delivery system, in vivo, tocotrienol, transferrin, tumor targeting.
Abstract: Despite its potent in vitro anti-cancer activity, the vitamin E extract tocotrienol has its therapeutic potential hampered by its poor bioavailability and by its inability to reach tumors in a specific way after intravenous administration. One possibility to overcome this issue would be to entrap tocotrienol within vesicles bearing transferrin, whose receptors are present in abundance on many cancer cell types. In this study, we demonstrated that the systemic administration of tocotrienol entrapped within transferrin-bearing vesicles led to tumor suppression of 20% of A431 epidermoid carcinoma tumors and 50% of B16-F10 melanoma tumors at the end of the treatment. The survival of animals treated with these vesicles was improved by more than 20 days in comparison with the controls, for the two cancer models tested. Animals did not show any secondary effects following administration of the treatment. The entrapment of tocotrienol within transferrin-bearing vesicles is therefore a promising therapeutic strategy, which could result in tumor suppression after systemic administration of this delivery system.
Export Options
About this article
Cite this article as:
Fu Yen Ju and Dufes Christine, Anti-Cancer Efficacy of Intravenously Administered Tumor- Targeted Vesicles Entrapping Tocotrienol, Pharmaceutical Nanotechnology 2014; 2 (4) . https://dx.doi.org/10.2174/2211738503666150119231232
DOI https://dx.doi.org/10.2174/2211738503666150119231232 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size
Current Drug Delivery Rat Resources in Biomedical Research
Current Pharmaceutical Biotechnology Asymmetric 1,3-Dipolar Cycloadditons of Stabilized Azomethine Ylides with Nitroalkenes
Current Topics in Medicinal Chemistry Artificial Sun Protection: Sunscreens and Their Carrier Systems
Current Drug Delivery An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets